Status
Conditions
Treatments
About
The goal of this clinical trial is to compare the clinical outcomes using different cetrorelix acetate in the context of a GnRH antagonist protocol for ovarian stimulation in women undergoing IVF or intracytoplasmic sperm injection(ICSI) treatment.The main question it aims to answer is whether the generic cetrorelix acetate is non-inferior to the reference product in the GnRH antagonist based protocol for women undergoing IVF. Ovarian stimulation was achieved by several types of follicle-stimulating hormone(FSH) or by FSH combined with luteinizing hormone activity. Daily dose of generic cetrorelix acetate (0.25 mg SC) or original cetrorelix acetate (0.25 mg SC) will be administered when the lead follicle was 14 mm. When more than two follicles reached 17 mm, oocyte maturation was triggered with 250 mcg of recombinant human chorionic gonadotropin.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Infertile couples plan to undergo IVF / ICSI pregnancy treatment into screening procedures and clinical study
Exclusion criteria
Subjects could not enter the study if they meet any one of the following criteria
Primary purpose
Allocation
Interventional model
Masking
1,338 participants in 2 patient groups
Loading...
Central trial contact
HE CAI, Doctor; Juanzi Shi, Doctor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal